Indicator, Reagent, or Diagnostic Aid – Page 6

Ultragenyx’s GTX-102 Shows Promising Results in Mid-Stage Angelman Syndrome Study, Pivotal Study on the Horizon

2 years ago talkbio0Tagged Angelman Syndrome, Antisense Oligonucleotides, Behavioral Improvement, Cognitive Improvement, Gross Motor Improvement, GTX-102, mid-stage study, Sleep Improvement, Ultragenyx

Ultragenyx, GTX-102, Angelman Syndrome, Mid-Stage Study, Pivotal Study, Antisense Oligonucleotide, Cognitive Improvement, Behavioral Improvement, Sleep Improvement, Gross Motor Improvement

Bristol Myers Squibb’s KRAZATI Confirmed Effective in Pivotal Phase 3 KRYSTAL-12 Trial Following Accelerated Approval

2 years ago talkbio0Tagged Accelerated Approval, adagrasib, Approved, bristol-myers, Clinical Benefit, Confirmatory Trial, Continuous, June 21/ 2024, KRASG12C mutation, KRAZATI, KRYSTAL-12, Locally, Metastatic to, Non-Small Cell Lung Carcinoma, ORR, Overall response rate, PDUFA, Primary Endpoint, Progression-Free Survival, squibb, United States Food and Drug Administration, Verification of Theories

Bristol Myers Squibb, KRAZATI (adagrasib), Pivotal Phase 3 trial, KRYSTAL-12 study, Primary endpoint met, Progression-free survival (PFS), Overall response rate (ORR), Confirmatory trial, Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, KRASG12C mutation, Accelerated approval, Continued approval contingent on clinical benefit verification, FDA assigned PDUFA goal date of June 21/ 2024

Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

2 years ago talkbio0Tagged Antisense Oligonucleotides, Genetic Epilepsy Drug, Infantile Severe Myoclonic Epilepsy, investor, Level of interest, Positive Clinical Trial, Seizures, STK-001, Stoke

Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm